Bijsterbosch M K, Van Berkel T J
Center for Bio-Pharmaceutical Sciences, University of Leiden, The Netherlands.
Biochem J. 1990 Aug 15;270(1):233-9. doi: 10.1042/bj2700233.
The liver contains two types of galactose receptors, specific for Kupffer and parenchymal cells respectively. These receptors are only expressed in the liver, and therefore are attractive targets for the specific delivery of drugs. We provided low-density lipoprotein (LDL), a particle with a diameter of 23 nm in which a variety of drugs can be incorporated, with terminal galactose residues by lactosylation. Radioiodinated LDL, lactosylated to various extents (60-400 mol of lactose/ mol of LDL), was injected into rats. The plasma clearance and hepatic uptake of radioactivity were correlated with the extent of lactosylation. Highly lactosylated LDL (greater than 300 lactose/LDL) is completely cleared from the blood by liver within 10 min. Pre-injection with N-acetylgalactosamine blocks liver uptake, which indicates that the hepatic recognition sites are galactose-specific. The hepatic uptake occurs mainly by parenchymal and Kupffer cells. At a low degree of lactosylation, approx. 60 lactose/LDL, the specific uptake (ng/mg of cell protein) is 28 times higher in Kupffer cells than in parenchymal cells. However, because of their much larger mass, parenchymal cells are the main site of uptake. At high degrees of lactosylation (greater than 300 lactose/LDL), the specific uptake in Kupffer cells is 70-95 times that in parenchymal cells. Under these conditions, Kupffer cells are, despite their much smaller mass, the main site of uptake. Thus not only the size but also the surface density of galactose on lactosylated LDL is important for the balance of uptake between Kupffer and parenchymal cells. This knowledge should allow us to design particulate galactose-bearing carriers for the rapid transport of various drugs to either parenchymal cells or Kupffer cells.
肝脏含有两种半乳糖受体,分别对库普弗细胞和实质细胞具有特异性。这些受体仅在肝脏中表达,因此是药物特异性递送的有吸引力的靶点。我们通过乳糖基化给低密度脂蛋白(LDL)(一种直径为23nm的颗粒,可掺入多种药物)提供了末端半乳糖残基。将不同程度乳糖基化(60 - 400摩尔乳糖/摩尔LDL)的放射性碘化LDL注入大鼠体内。放射性的血浆清除率和肝脏摄取与乳糖基化程度相关。高度乳糖基化的LDL(大于300个乳糖/LDL)在10分钟内被肝脏从血液中完全清除。预先注射N - 乙酰半乳糖胺可阻断肝脏摄取,这表明肝脏识别位点是半乳糖特异性的。肝脏摄取主要由实质细胞和库普弗细胞进行。在低乳糖基化程度时,约60个乳糖/LDL,库普弗细胞中的特异性摄取(纳克/毫克细胞蛋白)比实质细胞高28倍。然而,由于实质细胞的质量大得多,它们是摄取的主要部位。在高乳糖基化程度(大于300个乳糖/LDL)时,库普弗细胞中的特异性摄取是实质细胞的70 - 95倍。在这些条件下,尽管库普弗细胞的质量小得多,但它们是摄取的主要部位。因此,不仅乳糖基化LDL上半乳糖的大小,而且其表面密度对于库普弗细胞和实质细胞之间摄取的平衡都很重要。这一知识应使我们能够设计含半乳糖的颗粒载体,以便将各种药物快速转运至实质细胞或库普弗细胞。